# 4Kscore - LLMs.txt
> Generated by MCPner LLMs.txt Generator for WordPress
> Last updated: 2026-07-01T13:02:50-04:00
> Total items: 17
---
## Precision & Reliability
URL: https://www.4kscore.com/healthcare-provider/precision-reliability-the-science-behind-the-4kscore-test/
Type: page
Modified: 2026-06-12
Words: 239
> FDA-approved & validated in two prospective studies, the 4Kscore® Test delivers proven accuracy across diverse populations including African American men.
The Science BehindThe 4Kscore® Test The 4Kscore® Score Test is FDA-approved, and its accuracy has been demonstrated in two multi-center prospective validation studies in the United States. A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Test Accurately Identifies Men with High-grade Prostate Cancer Parekh et al. Eur Urol. 2015;68:464-470. 1012 men prospectively enrolled in 26 academic and community practices Subjects had scheduled prostate biopsy as recommended by a urologist and blood drawn prior to biopsy Minimum of 10 core TRUS-guided biopsies performed on all patients AUC = 0.82 36% of biopsies could be avoided or delayed A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men Study Results Show The 4Kscore Test Performance at 5.0 Cut-Point in the African American Population Identifies Men with High-Grade Prostate Cancer with 99% Sensitivity and 95% Negative Predictive Value (The 4Kscore Test PI) Punnen et al. J Urol. 2018;199(6):1459-1463. 8 Veterans Affairs Hospitals 56% of the 366 men were African American Similar 4Kscore performance to first validation study No significant difference in 4Kscore accuracy between African American and non-African American men Sensitivity of 97% and Negative Predictive Value (NPV) of 95% for the detection of aggressive prostate cancer
---
## When to Use the 4Kscore® Test?
URL: https://www.4kscore.com/healthcare-provider/when-to-use-the-4kscore-test/
Type: page
Modified: 2026-06-12
Words: 81
> Healthcare providers should order the 4Kscore® Test for men 45+ with an elevated PSA or abnormal DRE before initial or repeat negative biopsy.
When Should You Order The 4Kscore® Test? Men ≥45 years old with an age-specific elevated PSA or suspicious nodules with digital rectal exam (DRE), regardless of whether PSA is elevated Before initial or repeat negative biopsy Have no prior prostate cancer diagnosis Guideline-Aligned Care Recognized secondary testing prior to biopsy Both NCCN and AUA guidelines include the 4Kscore® Test as one of the biomarker tests that improve specificity for aggressive prostate cancer and reduce avoidable biopsies. AUA GuidelinesNCCN Guidelines
---
## Why Choose the 4Kscore® Test
URL: https://www.4kscore.com/healthcare-provider/why-physicians-choose-the-4kscore-test/
Type: page
Modified: 2026-06-12
Words: 191
> Studies have shown that the 4Kscore® Test helps providers confidently assess aggressive prostate cancer risk and reduce unnecessary biopsies.
Why Healthcare Providers Choose the 4Kscore® Test To Assess the Patient’s Probability of Aggressive Prostate Cancer Two US based, prospective validation studies, including a study performed at Veterans Health Administration facilities involving a predominantly African American population, resulted in combined intended use population of 937 subjects. At a cut-point of 5.0, the 4Kscore Test performance characteristics for the detection of Gleason Score (GS) ≥ 7 (aggressive prostate cancer) show: Sensitivity of 96.9% and Negative Predictive Value (NPV) of 95.9% with DRE information Sensitivity 97.6% and NPV of 96.4% if DRE information is unavailable Resulted in a meaningful reduction in avoidable prostate biopsies. Both studies demonstrated that the 4Kscore Test did not miss any Gleason 8 and higher on biopsy using the 4Kscore result at cut point of 5.0. The 4Kscore Test is included in the current NCCN and AUA prostate cancer early detection guidelines.1, 2 [1] American Urological Association (AUA). Early Detection of Prostate Cancer. auanet.org. Accessed 2026. [2] NCCN. Prostate Cancer Early Detection (V2.2026). nccn.org. Accessed 2026.
---
## What is the 4Kscore® Test
URL: https://www.4kscore.com/healthcare-provider/what-is-the-4kscore-prostate-cancer-biomarker-test/
Type: page
Modified: 2026-06-12
Words: 374
> The 4Kscore® Test integrates various test results and clinical data to calculate aggressive prostate cancer probability and reduce avoidable biopsies.
What is the 4Kscore® Prostate Cancer Biomarker Test? Using a clinically validated algorithm, The 4Kscore® Test integrates results of Total PSA, Free PSA, Intact PSA, Human Kallikrein 2 (hK2) plus age, prior biopsy status, and DRE (if available), and generates a probability score of detecting Gleason ≥7 / Grade Group ≥2 prostate cancer on biopsy. Clinical Utility Improve Risk Stratification The 4Kscore Test provides objective risk information beyond PSA alone, helping distinguish men who may benefit from biopsy from those who can be safely monitored. Reduce Avoidable Biopsies Studies demonstrate that the 4Kscore Test can help avoid upward of 30% of biopsies, depending on the risk threshold used, while preserving detection of aggressive disease. Support Shared Decision-Making The numeric risk output is intuitive for patients and aligns with guideline-driven discussions around benefits and harms of early detection. Guideline Alignment The 4Kscore Test is consistent with recommendations from leading professional organizations that endorse the use of secondary biomarkers prior to biopsy: Both the NCCN Prostate Cancer Early Detection Guidelines and The AUA/SUO Early Detection of Prostate Cancer Guideline recognize kallikrein-based tests as tools that may improve specificity and reduce avoidable procedures. Intended Use Population The 4Kscore Test is indicated for men age 45 and above, prostate biopsy naive or had a prior negative biopsy, and meet the age-specific elevated PSA or abnormal DRE defined below: Age-stratified PSA 45-54 years old: total PSA ≥ 2 ng/mL 55-75 years old: total PSA ≥ 3 ng/mL ≥76 years old: total PSA ≥ 4 ng/mL OR Suspicious nodule on DRE,regardless of whether PSA is elevated Contraindications The 4Kscore Test is Not Indicated in Men With: Digital rectal exam (DRE) performed within 96 hours (4 days) before blood draw. Use of 5-alpha reductase medication within previous 6 months. Prostate procedures within the previous six (6) months. Procedures include, but are not limited to, prostate biopsy, thermotherapy, microwave therapy, laser therapy, Transurethral Resection of the Prostate (TURP), urethral catheterization, and lower genitourinary tract endoscopy. Precautions The 4Kscore Test is: For in vitro diagnostic use For use by healthcare professionals Prescription use only Package Insert
---
## Patients & Elevated PSA Tests
URL: https://www.4kscore.com/healthcare-provider/patients-elevated-psa-tests/
Type: page
Modified: 2026-06-12
Words: 179
> Help your patients understand their elevated PSA with the 4Kscore® Test. This personalized risk assessment supports informed shared decision-making.
How 4Kscore® Can Help Your Patients Who Present With Age-Specific Elevated PSA The 4Kscore® Test is a blood test that provides a personalized risk assessment for aggressive (Gleason ≥7 / Grade Group ≥2) prostate cancer. It is intended for use in men with an age-stratified elevated PSA (prostate specific antigen) or suspicious nodule on DRE (digital rectal exam) who are considering whether to proceed to prostate biopsy. By combining the results of four kallikrein biomarkers, along with clinical information, such as age, DRE result (if available), and prior biopsy history (if any), the 4Kscore Test indicates the likelihood of finding aggressive prostate cancer, and helps healthcare providers and patients make more informed shared decisions whether a biopsy is beneficial. Why the Biopsy Decision Matters Prostate biopsy is not a benign procedure. While it remains the diagnostic gold standard, it carries potential risks and downstream consequences, including: Infection and sepsis Hematuria and hematospermia Urinary retention Overdiagnosis of indolent disease that may not require treatment Clinical guidelines increasingly emphasize risk stratification before biopsy, especially in men with modest PSA elevations.
---
## Frequently Asked Questions
URL: https://www.4kscore.com/patient/frequently-asked-questions-faqs/
Type: page
Modified: 2026-03-30
Words: 1159
> Get answers to common questions about the 4Kscore® Test, PSA testing, prostate biopsy, and what your results may mean. Make informed decisions.
What is PSA and why isn’t it a definitive test for prostate cancer? PSA (prostate-specific antigen) is a protein produced by the prostate and measured in the blood. Elevated levels can indicate prostate health issues, and PSA testing is the most common initial screening tool used for prostate cancer detection. However, an elevated PSA level is often caused by benign factors like prostate enlargement, inflammation, or infection. Although an elevated PSA test result can indicate that further evaluation is needed, it cannot reliably distinguish between aggressive cancer, slow-growing cancer, or non-cancerous conditions on its own. Can an elevated PSA mean something other than cancer? Yes. An elevated PSA does not necessarily mean prostate cancer is present. PSA levels can rise for a variety of non-cancerous reasons, including benign prostate enlargement (BPH), inflammation, infection, or recent activity that may affect the prostate (such as biking). Because PSA is not cancer-specific, additional evaluation is often needed to better understand what an elevated result may indicate before deciding on next steps. What does “aggressive prostate cancer” mean? Aggressive prostate cancer refers to forms of the disease that are more likely to grow quickly and spread beyond the prostate if left untreated. These types of prostate cancers differ from slow-growing, or indolent, cancers that may never cause symptoms or require treatment. Identifying whether aggressive prostate cancer is likely is an important part of prostate cancer detection, as it helps focus attention on cancers that may benefit from timely intervention while avoiding unnecessary procedures for lower-risk disease. What are the risks or side effects of a prostate biopsy? While a prostate biopsy is generally safe, like any invasive medical procedure, it can have side effects. These may include temporary bleeding in the urine or semen, discomfort, urinary symptoms, or infection. Most side effects are mild and resolve on their own, but more serious complications can occur in rare cases. Understanding the potential risks helps patients and healthcare providers weigh whether the benefits of a biopsy are likely to outweigh the downsides in an individual situation. Is a prostate biopsy always necessary if PSA is elevated? No. An elevated PSA does not automatically mean a prostate biopsy is necessary. PSA levels can rise for reasons other than cancer, including benign prostate enlargement (also known as BPH), inflammation, or infection. Additional evaluation can help clarify whether a biopsy is likely to provide useful information, and tools that offer more context about the likelihood of aggressive disease, like the 4Kscore® Test, can support a more informed discussion between patients and healthcare providers about next steps. What is the 4Kscore® Test? The 4Kscore Test is an FDA-approved blood test used to assess the likelihood of finding aggressive prostate cancer if a biopsy were performed. It is intended for men age 45 or older who have an age-specific elevated PSA result or an abnormal digital rectal exam (DRE), regardless of whether PSA is elevated. 4Kscore combines four prostate-related biomarkers with patient information, such as age and clinical history, into a single test. The result is a personalized probability estimate that supports informed discussions between patients and healthcare providers about whether a prostate biopsy may be appropriate. How is the 4Kscore® Test different from a PSA test? A PSA test measures the level of prostate-specific antigen in the blood, which can be elevated for many reasons beyond cancer. The 4Kscore Test goes further by combining multiple biomarkers and clinical factors to estimate the likelihood of aggressive prostate cancer. While PSA is a screening tool, the 4Kscore Test provides additional precision to help guide next steps, including whether a biopsy should be considered. What does my 4Kscore® result tell me? A 4Kscore result estimates the probability that aggressive prostate cancer would be found if a prostate biopsy were performed. Lower 4Kscore test results are associated with a lower likelihood of aggressive disease, while higher results suggest a higher likelihood. For example, a 4Kscore result below 5.0 has been associated with a decreased likelihood of finding aggressive prostate cancer on biopsy. The test does not diagnose prostate cancer but provides valuable additional information to support informed discussions between patients and providers about whether a biopsy may be appropriate. Your 4Kscore test result should be reviewed and discussed with your healthcare provider to decide the next steps in your care. Does the 4Kscore® Test diagnose prostate cancer? No. The 4Kscore Test does not diagnose prostate cancer. A prostate biopsy is the only way to confirm a diagnosis of prostate cancer. The 4Kscore Test provides meaningful information about the likelihood that aggressive prostate cancer would be fou...
---
## The 4Kscore® Test
URL: https://www.4kscore.com/patient/the-4kscore-test-clarity-before-a-prostate-biopsy/
Type: page
Modified: 2026-06-12
Words: 414
> The 4Kscore® Test is an FDA-approved blood test that helps predict your probability of aggressive prostate cancer before making a biopsy decision.
The 4Kscore® Test: Clarity Before a Prostate Biopsy The 4Kscore® Test is a non-invasive blood test that helps predict the likelihood of finding aggressive prostate cancer (defined as Gleason score ≥7 / Grade Group ≥2) before a biopsy decision. The test provides a probability score ranging from 1 to 95, which reflects your chance of finding aggressive prostate cancer on biopsy. A 4Kscore result of less than 5 suggests a very low likelihood of aggressive prostate cancer. The 4Kscore Test offers you and your healthcare provider dependable, data-driven precision in prostate biopsy decision making: Supported by two U.S. clinical validation studies. Evaluated in more than 100 published independent studies. Utilized by healthcare providers in over half a million men considering biopsy. In a major 2024 medical review of leading biomarker tests for assessing the likelihood of finding aggressive prostate cancer (blood and urine tests), the 4Kscore Test was ranked highest in diagnostic accuracy.1 The 4Kscore® TestValidation and Benefits The 4Kscore Test is highly accurate, allowing many men to safely avoid a prostate biopsy. Reduces the need for biopsies in low-risk men Studies show The 4Kscore Test can potentially help avert a significant number of avoidable biopsies, especially in low-risk men.2 Targets clinically significant cancers 4Kscore helps to focus on aggressive cancers that need treatment, while sparing low-risk cases from invasive procedures. Endorsed in guidelines 4Kscore is included in U.S., Canadian, and European guidelines for assisting biopsy decisions, including: Early detection of prostate cancer: AUA (American Urological Association) / SUO (Society of Urologic Oncology) Guideline2 The National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection3 Who Should Consider The 4Kscore® Test? Men who meet the criteria below: Age 45 years and older Age-specific elevated PSA: 45-54 years old – total PSA ≥ 2 ng/mL 55-75 years old – total PSA ≥ 3 ng/mL ≥76 years old – total PSA ≥ 4 ng/mL Abnormal digital rectal exam (DRE) results, regardless of PSA levels. No previous diagnosis of prostate cancer Never had a prostate biopsy or had a previous negative biopsy Contact your healthcare provider to find out more about the 4Kscore Test and whether it’s right for you. [1] Kawada T, et al. Eur Urol Oncol. 2024;7:390-401.[2] American Urological Association (AUA). Early Detection of Prostate Cancer. auanet.org. Accessed 2026. [3] NCCN. Prostate Cancer Early Detection (V2.2026). nccn.org. Accessed 2026.
---
## After an Elevated PSA
URL: https://www.4kscore.com/patient/after-an-elevated-psa/
Type: page
Modified: 2026-03-16
Words: 25
> An elevated PSA can mean many things beyond cancer. The 4Kscore® Test can help clarify your individual risk and guide your next steps.
When PSA results raise concern, additional tools such as The 4Kscore® Test may be used to better understand your individual risk before proceeding to biopsy.
---
## Prostate Biopsy
URL: https://www.4kscore.com/patient/is-a-prostate-biopsy-right-for-you/
Type: page
Modified: 2026-06-12
Words: 195
> Understand the prostate biopsy process, potential risks, and complications. Learn how the 4Kscore® Test can help you make a more informed biopsy decision.
Is a Prostate Biopsy Right for You? A prostate biopsy is an outpatient procedure where multiple small samples of tissue are taken from different areas of the prostate gland. A pathologist interprets those samples to determine whether there is cancer present or other conditions that cause an elevated PSA. If results are negative, you may continue regular monitoring; if positive, your healthcare provider will discuss treatment options. Potential Risks & Complications of a Prostate Biopsy Serious infection requiring antibiotics or hospitalization occurs in 0.8 to 3% of men.1 Blood in urine (hematuria) occurs in up to 50% of men, typically lasting a few days to a week.2 Blood in semen is very common and can persist for weeks or even months.2 Rectal bleeding is normal after transrectal biopsy. Rarely, clots may cause urinary blockage requiring temporary catheter use. About 25% of men experience temporary urinary symptoms like urgency or hesitancy post-biopsy. Acute urinary retention occurs in under 2% of men, often needing a brief catheterization until swelling subsides. [1] Loeb S, et al. BJU Int. 2013;112:577-588. [2] Wei JT, et al. J Urol. 2023;210:46-53.
---
## PSA Testing
URL: https://www.4kscore.com/patient/psa-testing/
Type: page
Modified: 2026-06-12
Words: 62
> A PSA test is the first step in prostate cancer screening, but it can't distinguish aggressive cancer from benign conditions. Learn what your results may mean.
PSA Testing: The First Step in Prostate Cancer Screening The PSA (prostate-specific antigen) test is a blood test associated with prostate health and the measurement of PSA is commonly used as an initial screening tool for prostate cancer. However, PSA is not cancer-specific, and PSA testing alone cannot differentiate between aggressive prostate cancer, indolent cancer, or other benign prostate conditions.
---
## Prostate Cancer
URL: https://www.4kscore.com/patient/prostate-cancer/
Type: page
Modified: 2026-06-12
Words: 346
> Learn about prostate cancer risks, diagnosis, and detection. Over 250,000 men are diagnosed each year. Understand your options before deciding on a biopsy
What to Know AboutProstate Cancer 250,000+ New prostate cancer diagnoses per year in the United States alone. Prostate cancer is the most diagnosed non-skin cancer in men.1 In recent years, the U.S. has seen about 250,000 to 315,000 new prostate cancer diagnoses per year, with incidence rising by roughly 3% annually since 2014.2 36,000+ Men are expected to die from prostate cancer in the U.S. this year. Prostate cancer often causes no noticeable symptoms, so screening is commonly used to detect changes before problems arise. An estimated 36,000 men will die from prostate cancer this year.3 1.7x Higher incidence in African American men than the overall male population. Of even deeper concern is the disproportionate impact prostate cancer has on the African American community. African American men are more likely to be diagnosed at a younger age, develop more aggressive disease, and have 1.7× higher incidence than the overall male population. Types of Prostate Cancer Some prostate cancers are indolent (slow-growing or low-risk) and may never cause symptoms or require treatment. Other prostate cancers are aggressive and more likely to grow, spread, and require treatment to prevent serious health consequences. A Modern Approach to Prostate Cancer Detection Identify Today, prostate cancer detection focuses on identifying aggressive disease while avoiding unnecessary treatment for cancers that are unlikely to impact health or quality of life. Test Screening often begins with a PSA (prostate specific antigen) blood test. When PSA results raise concern, additional tools such as The 4Kscore® Test may be used to better understand a patient’s risk before proceeding to biopsy. Biopsy A prostate biopsy is considered when the combined information suggests a meaningful risk of clinically significant (aggressive) prostate cancer. Prostate cancer can only be diagnosed with a tissue biopsy. [1] American Cancer Society. Cancer Facts & Figures 2026. cancer.org. Accessed 2026. [2] Siegel RL, et al. CA Cancer J Clin. 2024;74:12-49. [3] American Cancer Society. Key Statistics for Prostate Cancer. cancer.org. Accessed 2026.
---
## Terms of Use
URL: https://www.4kscore.com/terms-of-use/
Type: page
Modified: 2026-03-03
Words: 1191
> Your use of OPKO Health, Inc.'s Website at www.opko.com constitutes your acceptance of the terms and conditions of use ("Terms") contained herein. We encourage you to read and familiarize yourself with the...
Your use of OPKO Health, Inc.’s Website at www.opko.com constitutes your acceptance of the terms and conditions of use (“Terms”) contained herein. We encourage you to read and familiarize yourself with the Terms. Any rights not expressly granted herein are reserved. OPKO reserves the right to change the Terms hereof at any time. Users are responsible for regularly reviewing the Terms. Continued use of the Website following such changes shall constitute user’s acceptance of the changes. These Terms were last revised on November 9, 2009. Forward-Looking Information The information included in (or accessible from) this Website contains forward-looking statements that involve risks and uncertainties, including statements with respect to the safety, efficacy, potential benefits, and successful development of OPKO’s products under development. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, and the scope of the Company’s patent positions and litigation, among other factors, which are detailed in the company’s periodic reports filed with the Securities and Exchange Commission. Warranty Disclaimer This Website and all of the information it contains is provided for informational purposes only. You may download content only for your personal use for non-commercial purposes. No modification or further reproduction of the content is permitted. OPKO Health, Inc. and its subsidiary and affiliated companies make no representation about the suitability of the information on this Website for any purpose. This Website and all information is provided “as is” without warranty of any kind whether express or implied, including but not limited to implied warranties of merchantability and non-infringement, with respect to the site or any information contained on the site. There is no warranty, representation or guarantee related to the accuracy, timeliness or completeness of any information. OPKO does not warrant that the site and/or information will be free from defects, program limitations, viruses or other harmful components or that the site will be accessible and perform in accordance with your expectations. Use of the site is at your own risk. Content Disclaimer OPKO shall not be responsible for any errors or omissions contained in this Website. The Company reserves the right at its sole discretion to modify, supplement or delete the content of this site at any time or for any reason without notice. By use of the Website, the user acknowledges and accepts that the information published on the Website may contain technical or typographical errors or inaccuracies. License Disclaimer Use of this Website does not confer any license under any of OPKO’s or any third party’s intellectual property rights, whether by estoppels, implication or in any other manner. Links OPKO’s Website may provide links or reference to other sites. The links will allow you to leave the OPKO Website and enter other Websites. The links are provided to users as a service and are not sponsored by or affiliated with this Website or under the control of OPKO. No referenced or linked site implies endorsement, sponsorship, association or verification by OPKO of such referenced or linked site. OPKO is not responsible for, and makes no representation or warranties concerning the content of any of the referenced sites, or any linked site, or any link contained in a linked site. Your use of any referenced or linked site may be subject to terms and conditions contained in such site, which you should locate and review carefully prior to use. Trademarks Certain words, phrases, names, designs or logos used on this Website may constitute trademarks, service marks or trade names of OPKO or other entities. The display of any such marks or names on the Website does not imply that any license has been granted by OPKO or any other entity. The use of any OPKO trademarks or trade names without obtaining the prior written consent of OPKO is strictly prohibited. Compliance with Law You shall not use and/or access this Website and/or the information contained herein in any manner that will violate any applicable local, national, international or foreign law, including, but not limited to, any regulations having the force of law. Some jurisdictions may have restrictions on the use of the Internet by their residents. You agree not to impersonate another person in your use of the Website or the sending of any e-mail to an address listed on the Website. You may not use the Website in any manner which could damage, disable, overburden or impai...
---
## Accessibility
URL: https://www.4kscore.com/accessibility/
Type: page
Modified: 2026-03-13
Words: 601
> Our goal for this website is to provide information and access to services to all visitors. We understand that not everyone experiences web content the same way. Some have impaired...
Our goal for this website is to provide information and access to services to all visitors. We understand that not everyone experiences web content the same way. Some have impaired vision, hearing, ability to use a mouse or other disability. As part of our commitment to universal access, we make it a priority to take these differences into account by organizing our site and presenting our content in ways that are usable by visitors with disabilities and the assistive technologies they rely on. Here is more on web accessibility and this website: User Tips and Tools Your Internet user experience is shaped by more than just the design and content features built into the sites you visit. You also have available a growing number of alternative settings in your computer’s operating system and browser that can improve the clarity and accessibility of any site you visit. For example, many operating systems and browsers offer settings to change background colors, increase contrast, increase text and icon size, choose a preferred font, magnify your computer screen, and activate a screen reader that lets you listen to content you are unable to read. Accessibility Settings for Our Site Text size selector High contrast selector Accessibility Settings You Can Make Globally Your Computer’s Operating System Microsoft Windows – to learn more, visit Accessibility in Microsoft ProductsApple – to learn more, visit apple.com/accessibility Your Mobile Device Here are links to help you learn about “built-in” accessibility options available on your mobile device or tablet: IOS Devices: iPhone/iPads Android Devices Windows Devices Your Browser To learn about accessibility options on various browsers: Internet Explorer Mozilla Firefox Google Chrome Safari PDF Documents Our site content may include PDF documents that we or other sources have created. Most older PDFs, as well as many newer ones, are not compatible with screen-reader technology. Our goal is to reduce and eventually eliminate PDF content that is not recognizable by most screen-readers. Until we reach that goal, if you have difficulty accessing a PDF document at our website and would like information or assistance regarding its content, we will assist you. Please use our Feedback and Questions form to request assistance. Our Accessibility Policy This website is designed to provide information and access to services to all visitors, including those with disabilities. Our Accessibility Commitment We are committed to meeting the accessibility standards known as Web Content Accessibility Guidelines (WCAG) 2.1 AA. These have been adopted by W3C, the World Wide Web Consortium, as part of its Web Accessibility Initiative. Testing for Accessibility Problems Our web team tests our web pages using an online testing service to find and fix accessibility problems. From time to time our web team also asks persons with various types of disabilities to visit our site – or other sites with similar design and functionality – and provide their feedback and suggestions for changes we can make that will improve accessibility for all. Your Comments and Questions We also recognize the importance of feedback from community members who visit our site. We invite you to give us suggestions and feedback based on your experience while navigating our site. By all means, please let us know if you have questions or would like additional information. Feedback & Questions We’d like to hear from you. In providing feedback, please be specific about: the page, content, or function you are commenting on; the difficulty you are experiencing; and your suggestions for improving our site. You may contact us by . . . Complete and submit: Name(Required) First Last Email(Required) Phone Comment/Question/Suggestion:(Required) Δ
---
## Privacy Policy
URL: https://www.4kscore.com/privacy-policy/
Type: page
Modified: 2026-03-03
Words: 247
> What Do We Do With The Information You Provide? We may ask you to give us contact and demographic information when you register. We use this information to send our Site's users, like you, information...
What Do We Do With The Information You Provide? We may ask you to give us contact and demographic information when you register. We use this information to send our Site’s users, like you, information about the Site or Services. We also use this information to contact you both on line and offline when needed. What Do We Do With Your IP Address And Cookies? We use your IP address to help diagnose problems with our server and to administer our website. Your IP address is used to gather broad demographic information and is stored as a partial identifier. We use cookies, when applicable, to deliver content specific to your interests and when applicable to save your password so you don’t have to re-enter it each time you visit our site. You may set your browser to refuse cookies. If you make that choice, please understand that you may not be eligible for any specials and / or promotions we may offer our Site’s users. Is Your Personal Information Shared? No. Privacy Policy Changes We may amend this privacy policy from time to time. Contacting the Web Site If you have any questions about this privacy statement, the practices of this site, or use of our trademarks and copyrighted material, or for any other concerns please feel free to contact us.
---
## Contact
URL: https://www.4kscore.com/contact/
Type: page
Modified: 2026-06-12
Words: 216
> Have questions about the 4Kscore® Test, billing, or finding a draw center? Contact our support team at 833-4KSCORE or fill out our online form.
We’re Here to Help Whether you have questions about the 4Kscore® Test, need assistance finding a draw center, or have inquiries regarding your bill, our dedicated support team is ready to assist you. The 4Kscore® Test is performed byBioReference Laboratories, Inc.(an OPKO Health company). 481 Edward H. Ross DriveElmwood Park, NJ 07407CLIA #: 31D0652945CAP #: 1237201 For more information about The 4Kscore® Test, please call us at 833-4KSCORE (833-457-2673). For questions about your bill please call our dedicated hotline at 855-4KBILLING (855-452-4554). To pay an invoice from BioReference Health, LLC, please proceed to our secure online payment portal. Pay Bill* *By clicking this link, you will be directed to an external page for the BioReference payment portal. Name(Required) First Last Email(Required) Phone Zip Code(Required) I am a(Required) I am a…Healthcare ProviderPatientPatient Family MemberOther Other Reason for Inquiry(Required) Reason for InquiryFind a Draw CenterPhysician/Provider InquiryGeneral Question Message/Comment(Required) Notice: This form is not for transmitting personal health information. Please do not include details about your medical history or condition. For confidential matters, contact us by phone. Δ
---
## Draw Centers
URL: https://www.4kscore.com/draw-centers/
Type: page
Modified: 2026-06-12
Words: 50
> Locate a convenient blood draw center near you to get the 4Kscore® Test. Call 1-833-457-2673 for information on patient service center locations in your area.
Find a Draw Center forThe 4Kscore® Test If your physician does not perform blood draws in-office, you can visit a conveniently located patient service center. For information about service centers in your area, please contact the 4Kscore® Customer Service Hotline at 833-4KSCORE (833-457-2673).
---
## Home
URL: https://www.4kscore.com/
Type: page
Modified: 2026-03-30
Words: 346
> An elevated PSA isn't a diagnosis. The 4Kscore® Test is an FDA-approved blood test that assesses your risk of aggressive prostate cancer before biopsy.
Elevated PSA Result? It doesn’t necessarily mean that you need a biopsy or have prostate cancer. Prostate Cancer Patients Understanding prostate cancer and what an elevated PSA result can mean for you. Patients & Elevated PSA Tests Healthcare Providers How the 4Kscore® Test can help inform your patients about next steps after an elevated PSA. In America, a Man Is Diagnosed With Prostate Cancer Every Two Minutes1 Know where you stand Prostate Cancer Early Detection Is Key 99% Is the 5-year relative survival rate for prostate cancer that has not spread to other parts of the body.2 Don’t Wait To Screen 45 Is the recommended age to start prostate cancer screening.3 Prostate Cancer Is Not Rare 12% Lifetime risk of being diagnosed with prostate cancer. Elevated Risk in African American Men 1.7x More likely to be diagnosed with prostate cancer.4 An Elevated PSA is the Beginning of the Story, Not the End Most elevated PSA results are caused by factors other than cancer. If your PSA level is elevated, find out how the 4Kscore Test can provide the clarity you and your healthcare provider need to decide next steps. Elevated PSA Results Assessing Aggressive Prostate Cancer Probability With The 4Kscore® Test. The 4Kscore Test is an FDA-approved blood test that provides you with a clear, personalized probability of finding aggressive prostate cancer on biopsy. 4Kscore offers you actionable information to make a better-informed prostate biopsy decision just when it matters most. 4Kscore is included in the American Urological Association (AUA) and National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection. The 4Kscore Test FDA Approved U.S. Food & Drug Administration AUA Guidelines American Urological Association NCCN Guidelines National Comprehensive Cancer Network [1] Prostate Cancer Foundation. 2026. pcf.org. Accessed 2026. [2] National Cancer Institute (NCI). SEER Training. training.seer.cancer.gov. Accessed 2026. [3] National Comprehensive Cancer Network (NCCN). Prostate Cancer Early Detection (V2.2026). nccn.org. Accessed 2026. [4] National Cancer Institute (NCI). Cancer Health Disparities. cancer.gov. Accessed 2026.
---